Financhill
Sell
18

EDAP Quote, Financials, Valuation and Earnings

Last price:
$1.78
Seasonality move :
-7.05%
Day range:
$1.75 - $1.80
52-week range:
$1.26 - $6.01
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.99x
P/B ratio:
1.78x
Volume:
17.3K
Avg. volume:
66.1K
1-year change:
-69.15%
Market cap:
$66.6M
Revenue:
$69.4M
EPS (TTM):
-$0.61

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EDAP
Edap TMS SA
$16.6M -$0.17 -2.39% -4.81% $5.75
ADAP
Adaptimmune Therapeutics PLC
$6.6M -$0.17 -91.39% -8.33% $1.58
AKTX
Akari Therapeutics PLC
-- -- -- -- --
CLLS
Cellectis SA
$13.8M -- 36.24% -100% $5.60
DBVT
DBV Technologies SA
$501.4K -$0.24 -- -87.99% $14.76
GNFT
Genfit SA
$151.2M -- -- -- $8.70
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EDAP
Edap TMS SA
$1.78 $5.75 $66.6M -- $0.00 0% 0.99x
ADAP
Adaptimmune Therapeutics PLC
$0.29 $1.58 $77.5M -- $0.00 0% 0.42x
AKTX
Akari Therapeutics PLC
$1.35 -- $43.4M -- $0.00 0% --
CLLS
Cellectis SA
$1.46 $5.60 $146.4M -- $0.00 0% 2.99x
DBVT
DBV Technologies SA
$8.35 $14.76 $228.4M -- $0.00 0% --
GNFT
Genfit SA
$4.51 $8.70 $225.5M 32.57x $0.00 0% 3.13x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EDAP
Edap TMS SA
17.49% -0.651 10.79% 1.16x
ADAP
Adaptimmune Therapeutics PLC
-211.44% 3.631 50.03% 1.57x
AKTX
Akari Therapeutics PLC
-- -2.630 -- --
CLLS
Cellectis SA
30.41% 0.907 56.64% 1.64x
DBVT
DBV Technologies SA
-- -3.919 -- --
GNFT
Genfit SA
-- 0.519 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EDAP
Edap TMS SA
$6M -$6.3M -43.34% -49.1% -44.23% -$6.6M
ADAP
Adaptimmune Therapeutics PLC
$6.4M -$44.1M -107.36% -199.63% -619.47% -$67.8M
AKTX
Akari Therapeutics PLC
-- -$3.5M -- -- -- -$2.2M
CLLS
Cellectis SA
$8.6M -$14.2M -35.55% -49.15% -152.19% -$17.6M
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
GNFT
Genfit SA
-- -- -- -- -- --

Edap TMS SA vs. Competitors

  • Which has Higher Returns EDAP or ADAP?

    Adaptimmune Therapeutics PLC has a net margin of -52.18% compared to Edap TMS SA's net margin of -653.18%. Edap TMS SA's return on equity of -49.1% beat Adaptimmune Therapeutics PLC's return on equity of -199.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    42.01% -$0.20 $45.2M
    ADAP
    Adaptimmune Therapeutics PLC
    87.93% -$0.18 -$12M
  • What do Analysts Say About EDAP or ADAP?

    Edap TMS SA has a consensus price target of $5.75, signalling upside risk potential of 223.03%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.58 which suggests that it could grow by 438.89%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Edap TMS SA, analysts believe Adaptimmune Therapeutics PLC is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 2 0
    ADAP
    Adaptimmune Therapeutics PLC
    3 3 0
  • Is EDAP or ADAP More Risky?

    Edap TMS SA has a beta of 0.128, which suggesting that the stock is 87.225% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.857, suggesting its more volatile than the S&P 500 by 185.668%.

  • Which is a Better Dividend Stock EDAP or ADAP?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or ADAP?

    Edap TMS SA quarterly revenues are $14.3M, which are larger than Adaptimmune Therapeutics PLC quarterly revenues of $7.3M. Edap TMS SA's net income of -$7.4M is higher than Adaptimmune Therapeutics PLC's net income of -$47.6M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.99x versus 0.42x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    0.99x -- $14.3M -$7.4M
    ADAP
    Adaptimmune Therapeutics PLC
    0.42x -- $7.3M -$47.6M
  • Which has Higher Returns EDAP or AKTX?

    Akari Therapeutics PLC has a net margin of -52.18% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -49.1% beat Akari Therapeutics PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    42.01% -$0.20 $45.2M
    AKTX
    Akari Therapeutics PLC
    -- -- --
  • What do Analysts Say About EDAP or AKTX?

    Edap TMS SA has a consensus price target of $5.75, signalling upside risk potential of 223.03%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 5825.93%. Given that Akari Therapeutics PLC has higher upside potential than Edap TMS SA, analysts believe Akari Therapeutics PLC is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 2 0
    AKTX
    Akari Therapeutics PLC
    0 0 0
  • Is EDAP or AKTX More Risky?

    Edap TMS SA has a beta of 0.128, which suggesting that the stock is 87.225% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.287, suggesting its less volatile than the S&P 500 by 71.306%.

  • Which is a Better Dividend Stock EDAP or AKTX?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or AKTX?

    Edap TMS SA quarterly revenues are $14.3M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Edap TMS SA's net income of -$7.4M is lower than Akari Therapeutics PLC's net income of -$3.7M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.99x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    0.99x -- $14.3M -$7.4M
    AKTX
    Akari Therapeutics PLC
    -- -- -- -$3.7M
  • Which has Higher Returns EDAP or CLLS?

    Cellectis SA has a net margin of -52.18% compared to Edap TMS SA's net margin of -170.14%. Edap TMS SA's return on equity of -49.1% beat Cellectis SA's return on equity of -49.15%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    42.01% -$0.20 $45.2M
    CLLS
    Cellectis SA
    81.09% -$0.18 $167M
  • What do Analysts Say About EDAP or CLLS?

    Edap TMS SA has a consensus price target of $5.75, signalling upside risk potential of 223.03%. On the other hand Cellectis SA has an analysts' consensus of $5.60 which suggests that it could grow by 283.56%. Given that Cellectis SA has higher upside potential than Edap TMS SA, analysts believe Cellectis SA is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 2 0
    CLLS
    Cellectis SA
    2 1 0
  • Is EDAP or CLLS More Risky?

    Edap TMS SA has a beta of 0.128, which suggesting that the stock is 87.225% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.107, suggesting its more volatile than the S&P 500 by 210.711%.

  • Which is a Better Dividend Stock EDAP or CLLS?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or CLLS?

    Edap TMS SA quarterly revenues are $14.3M, which are larger than Cellectis SA quarterly revenues of $10.7M. Edap TMS SA's net income of -$7.4M is higher than Cellectis SA's net income of -$18.1M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.99x versus 2.99x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    0.99x -- $14.3M -$7.4M
    CLLS
    Cellectis SA
    2.99x -- $10.7M -$18.1M
  • Which has Higher Returns EDAP or DBVT?

    DBV Technologies SA has a net margin of -52.18% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -49.1% beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    42.01% -$0.20 $45.2M
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About EDAP or DBVT?

    Edap TMS SA has a consensus price target of $5.75, signalling upside risk potential of 223.03%. On the other hand DBV Technologies SA has an analysts' consensus of $14.76 which suggests that it could grow by 76.75%. Given that Edap TMS SA has higher upside potential than DBV Technologies SA, analysts believe Edap TMS SA is more attractive than DBV Technologies SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 2 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is EDAP or DBVT More Risky?

    Edap TMS SA has a beta of 0.128, which suggesting that the stock is 87.225% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

  • Which is a Better Dividend Stock EDAP or DBVT?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or DBVT?

    Edap TMS SA quarterly revenues are $14.3M, which are larger than DBV Technologies SA quarterly revenues of --. Edap TMS SA's net income of -$7.4M is higher than DBV Technologies SA's net income of -$27.1M. Notably, Edap TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.99x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    0.99x -- $14.3M -$7.4M
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
  • Which has Higher Returns EDAP or GNFT?

    Genfit SA has a net margin of -52.18% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -49.1% beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    42.01% -$0.20 $45.2M
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About EDAP or GNFT?

    Edap TMS SA has a consensus price target of $5.75, signalling upside risk potential of 223.03%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 92.96%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    0 2 0
    GNFT
    Genfit SA
    1 0 0
  • Is EDAP or GNFT More Risky?

    Edap TMS SA has a beta of 0.128, which suggesting that the stock is 87.225% less volatile than S&P 500. In comparison Genfit SA has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.105%.

  • Which is a Better Dividend Stock EDAP or GNFT?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or GNFT?

    Edap TMS SA quarterly revenues are $14.3M, which are larger than Genfit SA quarterly revenues of --. Edap TMS SA's net income of -$7.4M is higher than Genfit SA's net income of --. Notably, Edap TMS SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 0.99x versus 3.13x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    0.99x -- $14.3M -$7.4M
    GNFT
    Genfit SA
    3.13x 32.57x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Asana Stock Be in 5 Years?
Where Will Asana Stock Be in 5 Years?

Asana stock hasn’t given many investors on Wall Street any…

Where Will Dell Stock Be in 5 Years?
Where Will Dell Stock Be in 5 Years?

So you’re looking at Dell (NASDAQ: DELL) and wondering, “Is…

Where Will Cameco Stock Be in 5 Years?
Where Will Cameco Stock Be in 5 Years?

Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
82
SBET alert for May 31

SharpLink Gaming [SBET] is down 3.17% over the past day.

Buy
55
RGC alert for May 31

Regencell Bioscience Holdings [RGC] is up 16.13% over the past day.

Buy
56
SVT alert for May 31

Servotronics [SVT] is up 0.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock